A single-centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease.

ABSTRACT:

Aims

Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower-cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes and associated psychosocial variables in a group of patients undergoing a nonmedical switch to biosimilar adalimumab.

Methods

Patients with inflammatory bowel disease (IBD) were followed before and after switching from Humira to Amgevita. Objective disease activity was assessed pre- and post-switch using the Harvey-Bradshaw Index (Crohn's disease) or partial Mayo score (ulcerative colitis), faecal calprotectin and C-reactive p

SUBMITTER: Rabbitt L 

PROVIDER: S-EPMC12381624 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature